These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 12832230

  • 1. Axonal degeneration and progressive neurologic disability in multiple sclerosis.
    Bjartmar C, Trapp BD.
    Neurotox Res; 2003; 5(1-2):157-64. PubMed ID: 12832230
    [Abstract] [Full Text] [Related]

  • 2. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease.
    Bjartmar C, Wujek JR, Trapp BD.
    J Neurol Sci; 2003 Feb 15; 206(2):165-71. PubMed ID: 12559505
    [Abstract] [Full Text] [Related]

  • 3. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys.
    Rosenzweig-Lipson S, Bergman J.
    Eur J Pharmacol; 1994 Aug 01; 260(2-3):237-41. PubMed ID: 7988649
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase.
    Deveney AM, Waddington JL.
    Br J Pharmacol; 1995 Oct 01; 116(3):2120-6. PubMed ID: 8640354
    [Abstract] [Full Text] [Related]

  • 5. Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis.
    Singh S, Dallenga T, Winkler A, Roemer S, Maruschak B, Siebert H, Brück W, Stadelmann C.
    J Neuroinflammation; 2017 Mar 17; 14(1):57. PubMed ID: 28302146
    [Abstract] [Full Text] [Related]

  • 6. [Neuronal injury in multiple sclerosis].
    Correale J, Meli F, Ysrraelit C.
    Medicina (B Aires); 2006 Mar 17; 66(5):472-85. PubMed ID: 17137182
    [Abstract] [Full Text] [Related]

  • 7. Axonal pathology in multiple sclerosis: relationship to neurologic disability.
    Trapp BD, Ransohoff R, Rudick R.
    Curr Opin Neurol; 1999 Jun 17; 12(3):295-302. PubMed ID: 10499174
    [Abstract] [Full Text] [Related]

  • 8. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis.
    Wujek JR, Bjartmar C, Richer E, Ransohoff RM, Yu M, Tuohy VK, Trapp BD.
    J Neuropathol Exp Neurol; 2002 Jan 17; 61(1):23-32. PubMed ID: 11829341
    [Abstract] [Full Text] [Related]

  • 9. Neuronal injury in chronic CNS inflammation.
    Zindler E, Zipp F.
    Best Pract Res Clin Anaesthesiol; 2010 Dec 17; 24(4):551-62. PubMed ID: 21619866
    [Abstract] [Full Text] [Related]

  • 10. Behavioural evidence for "D-1-like" dopamine receptor subtypes in rat brain using the new isochroman agonist A 68930 and isoquinoline antagonist BW 737C.
    Daly SA, Waddington JL.
    Psychopharmacology (Berl); 1993 Dec 17; 113(1):45-50. PubMed ID: 7862827
    [Abstract] [Full Text] [Related]

  • 11. Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.
    Antkiewicz-Michaluk L, Michaluk J, Romańska I, Papla I, Vetulani J.
    J Neural Transm (Vienna); 2000 Dec 17; 107(8-9):1009-19. PubMed ID: 11041279
    [Abstract] [Full Text] [Related]

  • 12. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat.
    Papadopoulos D, Pham-Dinh D, Reynolds R.
    Exp Neurol; 2006 Feb 17; 197(2):373-85. PubMed ID: 16337942
    [Abstract] [Full Text] [Related]

  • 13. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
    Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD.
    Psychopharmacology (Berl); 1995 Feb 17; 117(4):403-12. PubMed ID: 7604140
    [Abstract] [Full Text] [Related]

  • 14. Apomorphine-induced context-specific behavioural sensitization is prevented by the D1 antagonist SCH-23390 but potentiated and uncoupled from contextual cues by the D2 antagonist sulpiride.
    Dias FR, Carey RJ, Carrera MP.
    Psychopharmacology (Berl); 2010 Apr 17; 209(2):137-51. PubMed ID: 20177884
    [Abstract] [Full Text] [Related]

  • 15. Axonal loss in multiple sclerosis: causes and mechanisms.
    Criste G, Trapp B, Dutta R.
    Handb Clin Neurol; 2014 Apr 17; 122():101-13. PubMed ID: 24507515
    [Abstract] [Full Text] [Related]

  • 16. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
    Cristofanilli M, Rosenthal H, Cymring B, Gratch D, Pagano B, Xie B, Sadiq SA.
    Exp Neurol; 2014 Nov 17; 261():620-32. PubMed ID: 25111532
    [Abstract] [Full Text] [Related]

  • 17. The Ras homolog Rhes affects dopamine D1 and D2 receptor-mediated behavior in mice.
    Quintero GC, Spano D, Lahoste GJ, Harrison LM.
    Neuroreport; 2008 Oct 29; 19(16):1563-6. PubMed ID: 18845937
    [Abstract] [Full Text] [Related]

  • 18. Evidence for dopamine 'D1-like' receptor subtypes in the behavioural effects of two new selective antagonists, LY 270411 and BW 737C.
    Deveney AM, Waddington JL.
    Eur J Pharmacol; 1996 Dec 19; 317(2-3):175-81. PubMed ID: 8997598
    [Abstract] [Full Text] [Related]

  • 19. Antidopaminergic effects of bisbenzyl and benzyl tetrahydroisoquinoline alkaloids.
    Watanabe H, Uramoto H, Maeda-Hagiwara M, Kikuchi T.
    Arch Int Pharmacodyn Ther; 1985 Nov 19; 278(1):53-60. PubMed ID: 3938207
    [Abstract] [Full Text] [Related]

  • 20. Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures.
    Guo H, Tang Z, Yu Y, Xu L, Jin G, Zhou J.
    Eur J Neurosci; 2002 Nov 19; 16(10):1861-70. PubMed ID: 12453049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.